Integrated Deductible

An integrated deductible is a type of health insurance plan design that combines deductibles for both medical and prescription drug expenses. With an integrated deductible, the member's out-of-pocket expenses for both medical and prescription drugs are combined and applied to a single deductible amount. Once the deductible is met, the plan typically begins to cover the costs of both medical and prescription drugs.

Here are some key features of an integrated deductible:

• Combines medical and prescription drug expenses: An integrated deductible combines both medical and prescription drug expenses into a single deductible amount.

• Helps meet deductible faster: Because medical and prescription drug expenses are combined, members can reach their deductible faster than if they had separate deductibles.

• Lower out-of-pocket costs: Once the deductible is met, the plan begins to cover the costs of both medical and prescription drugs, resulting in lower out-of-pocket costs for the member.

• Encourages cost-consciousness: An integrated deductible can encourage members to be more cost-conscious when making healthcare decisions because they are responsible for the full cost of medical and prescription drug expenses until they meet their deductible.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.